Advertisement
Opioid News
May 26, 2017
May 26, 2017
With so much attention directed toward preventing and curtailing prescription opioid abuse, pharmacists should be careful not to miss the signs of...
What pharmacists should be aware of and steps to take
May 22, 2017
May 22, 2017
Opioid use during pregnancy may be linked to various birth defects, but much of the research published in the literature is older, flawed in...
Literature review calls for stronger studies in light of current opioid crisis
April 18, 2017
Most of us are engaged in one way or another in supporting patients with pain or assisting those with substance use disorder. To demonstrate the...
April 17, 2017
April 17, 2017
It seems not a day goes by without a headline about the opioid crisis, yet for all the media blitz, many parents may be missing a crucial point...
Information about safety shouldn’t get lost in the buzz about opioids
April 11, 2017
April 11, 2017
While still encouraging their implementation, CMS’s final call letter does not require sponsors to incorporate hard opioid safety edits at the 200-...
CMS’s final call letter addresses several issues raised by APhA
April 03, 2017
April 03, 2017
JAPhA has published a special issue entitled “Opioids, Naloxone, and Beyond: The Intersection of Medication Safety, Public Health, and Pharmacy.”...
30 articles on a timely topic for pharmacists
April 03, 2017
April 03, 2017
Patients who take opioids for more than 5 days are more likely to continue taking them long-term, according to a study appearing in CDC’s March 17...
MMWR report describes characteristics of long-term opioid users
March 25, 2017
March 25, 2017
Keynote speaker Elliot J. Krane, MD, punctured myths about opioids and addiction in an electric, riveting presentation to attendees at the Opening...
Pain physician Krane delivers keynote at Opening General Session
February 21, 2017
February 21, 2017
At the start of 2017, FDA approved two new abuse-deterrent opioids. Morphine sulfate (Arymo—Egalet) extended-release (ER) was given agency approval...
Experts are split on whether opioids with abuse-deterrent properties are the best answer to the prescription opioid abuse epidemic
January 03, 2017
January 03, 2017
FDA Center for Drug and Evaluation and Research Director Janet Woodcock, MD, joined the agency’s December 20, 2016, podcast to discuss the agency’s...
Opioid Action Plan initiatives include approval of warning label language and Medication Guides, potential addition of IR opioids to REMS program
